Artwork

Konten disediakan oleh BioTech Nation Team and Moira Gunn. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh BioTech Nation Team and Moira Gunn atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology

19:52
 
Bagikan
 

Manage episode 428175792 series 3360496
Konten disediakan oleh BioTech Nation Team and Moira Gunn. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh BioTech Nation Team and Moira Gunn atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.

  continue reading

106 episode

Artwork
iconBagikan
 
Manage episode 428175792 series 3360496
Konten disediakan oleh BioTech Nation Team and Moira Gunn. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh BioTech Nation Team and Moira Gunn atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.

  continue reading

106 episode

Semua episode

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat